Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
A small study of 20 people with Parkinson's disease found virtual house calls provide clinical benefits comparable to in-person physician office visits, saving patients and caregivers time and travel. The study also found no difference in quality-of-life changes between the two groups.
A new NIH-funded collaboration aims to accelerate the search for biomarkers in Parkinson's disease by improving collaboration among researchers and involving patients in clinical studies. The initiative, led by Dr. Clemens Scherzer at Brigham and Women's Hospital, seeks to develop biomarkers that can predict, diagnose, or monitor the d...
Researchers have discovered a critical link between impaired protein digestion in neurons and familial Parkinson's disease. The study identifies LRRK2 mutations as a key contributor to alpha-synuclein accumulation, providing potential avenues for drug treatments or genetic therapies.
Scientists at UCSF have discovered a way to detect abnormal brain rhythms associated with Parkinson's disease by implanting electrodes within the brains of people with the disease. This finding may lead to developing next-generation brain stimulation devices to alleviate symptoms.
Researchers at Albert Einstein College of Medicine have discovered how the most common genetic mutations in familial Parkinson's disease damage brain cells. The study found that abnormal LRRK2 protein disrupts a 'garbage-disposal' process, leading to toxic levels of alpha-synuclein and neuronal death.
Researchers identified a novel signal transduction pathway that activates parkin and prevents stress-induced neuronal cell death in Parkinson's disease. The parkin gene plays a crucial role in maintaining mitochondrial integrity, which is essential for preventing cell death.
Miniature, ultra-flexible electrodes developed in Switzerland may improve Deep Brain Stimulation (DBS) treatment for Parkinson's disease and other conditions. These new electrodes allow for more precise directional stimulation, reducing side effects and enhancing therapeutic effectiveness.
Researchers at the University of York have established a link between Parkinson's and visual problems in an animal model. A study found that a common genetic mutation triggering Parkinson's affects eye nerve cell function, leading to gradual loss of vision.
Researchers identified a protein trafficking defect in brain cells that may underlie common non-familial forms of Parkinson's disease. The defect is related to genetic variants in two genes, LRRK2 and RAB7L1, which disrupt protein sorting and lead to the accumulation of protein aggregates.
A study published in JAMA Neurology found no evidence of human-to-human transmission of AD and PD protein in cadaver-derived hGH recipients, contradicting previous concerns. The research included 34 autopsy patients and a group of c-hGH recipients, yielding no cases of AD or PD.
The R1441G mutation, known as the Basque mutation, is a genetic variation that increases the risk of developing Parkinson's disease. A study published in Neurogenetics and Movement Disorders found that individuals carrying this mutation have an 83% chance of developing the disease by age 80.
Researchers have identified mitochondrial CYP2D6 as a potential target for mitigating Parkinson's disease. The study found that mitochondrial CYP2D6 can effectively metabolize MPTP, a compound causing brain cell damage in Parkinson's, and that inhibiting its activity reduces neuronal degeneration.
The NIH has launched a collaborative effort to find biomarkers for Parkinson's disease, which could help predict, diagnose, or monitor the condition. Researchers are exploring various approaches, including non-invasive imaging and protein analysis, to identify potential biomarkers that could improve treatment outcomes.
Research at Tel Aviv University finds that Parkinson's patients taking dopamine-enhancing medications are developing artistic talents, including painting, sculpting, and writing. The study suggests a link between dopamine levels and creativity, with some patients exhibiting increased impulsivity and lower inhibitions.
A new study published in Neurology shows that people with early Parkinson's disease often experience non-motor symptoms like anxiety, constipation, and drooling. These symptoms can significantly impact quality of life and are treatable if addressed.
Researchers have discovered a potential new method for diagnosing Parkinson's disease by testing the saliva gland. The study found that abnormal proteins associated with the disease were consistently present in the submandibular salivary glands of patients, suggesting this non-invasive test could be used to diagnose living individuals.
Researchers found blocking JNK interaction with Sab can protect against neuronal damage, suggesting a potential new target for drug development. The study also showed that inhibiting JNK signaling leaves other cell signaling intact, which could mean fewer side effects in future therapies.
Researchers at Mayo Clinic have discovered that testing a portion of the saliva gland may diagnose Parkinson's disease more accurately. The study found abnormal proteins associated with the disease in nine out of 11 patients, offering hope for improved diagnosis and treatment.
Researchers found no link between untreated Parkinson's and impulse control disorders. However, studies suggest that exposure to dopamine-related drugs may increase impulsive behaviors in patients with the disease.
Researchers found no correlation between Parkinson's disease itself and impulse control symptoms, contradicting previous studies. The study suggests that dopamine-related medications may be the primary cause of these disorders.
Researchers found that benomyl exposure can trigger a cascade of cellular events leading to Parkinson's disease, even in individuals without prior pesticide exposure. The study suggests developing new drugs to protect ALDH activity may slow disease progression.
A small stroke, known as a silent stroke, can cause Parkinson's disease by killing dopaminergic neurons in the substantia nigra. The study found inflammation and brain damage following the stroke, leading to neurodegeneration and potential onset of Parkinson's disease.
Researchers at Rice University have discovered a new way to monitor protein aggregation in living cells, which could lead to the development of drugs that break up fibrils. The metallic probe, made of ruthenium, binds with misfolded alpha-synuclein proteins and can be tracked using photoluminescence spectroscopy.
A study by Massachusetts General Hospital researchers found that mice with elevated urate levels showed significantly less neurodegeneration and improved movement abnormalities compared to those with low urate levels. The results support the possibility that increasing urate levels may slow progression of Parkinson's disease.
Researchers at AxoGlia Therapeutics and the Luxembourg Centre for Systems Biomedicine have received a grant to identify new neuroprotective therapeutic targets for Parkinson's disease. The project aims to disrupt the CD40/CD40-Ligand neuroinflammatory pathway, which could lead to new avenues for therapeutic interventions.
Researchers developed a way to derive dopaminergic neurons from adult bone marrow stem cells in monkeys. The new neurons were then transplanted into the same monkeys with induced Parkinson's disease, showing significant improvement in motor function.
Researchers at Rensselaer Polytechnic Institute have created novel antibodies that can prevent the formation of toxic protein particles linked to diseases such as Alzheimer's and Parkinson's. These antibodies bind to 10 proteins per molecule, making them more potent inhibitors than conventional antibodies.
Researchers found that GM1 ganglioside improved symptoms and slowed disease progression in patients with Parkinson's disease over a 2.5-year period. The study enrolled 77 subjects and followed them for 120 weeks, with significant benefits observed when participants stopped taking the drug.
A study found that exercise programs on stationary bicycles improve Parkinson's disease symptoms, with faster pedaling leading to greater brain connectivity and motor ability improvements. The therapy is low-cost and effective, even for patients who don't need forced-rate exercise.
A new MRI technique has provided the first clinical evidence for the theory that Parkinson's neurodegeneration begins deep in the brain and advances upward. The study found significant loss of volume in the substantia nigra early on, followed by loss of basal forebrain volume later in the disease.
A new diagnostic method for Parkinson's disease is noninvasive and effective in over 90% of cases. The method tracks speech patterns to detect the disorder's early signs.
A Scripps Research Institute team has identified a key factor controlling damage to brain cells in a mouse model of Parkinson's disease. The discovery, led by scientist Bruno Conti, points to the IL-13 receptor as a potential target for new treatment options.
Researchers discovered that yeast protein Hsp104 can break up both amyloid fibrils and disordered protein clumps, with different requirements for stability. This finding offers a new approach to eliminate toxic clumps linked with neurodegenerative diseases.
Researchers at the University of Pennsylvania School of Medicine have found that injecting synthetic, misfolded α-Syn protein into healthy mice recapitulates Parkinson's disease progression, leading to dopamine neuron death and Lewy body formation. The study establishes a mechanistic link between α-Syn transmission and neurodegeneration.
A new study published by the American Academy of Neurology reveals a significant link between head injuries and pesticide exposure to an increased risk of Parkinson's disease. People with Parkinson's were found to be three times more likely to have had a head injury and exposure to paraquat, a common herbicide.
The University of Granada and the Michael J. Fox Foundation have developed advanced imaging techniques to diagnose Parkinson's disease, improving accuracy and reducing reliance on expert analysis. The new methods utilize machine learning algorithms to analyze brain function and image data, demonstrating promising results in diagnosis.
Researchers have created a new family of compounds that could slow Parkinson's disease progression by shutting down the Cav1.3 channel, which allows calcium to flood into dopamine neurons. The compounds were developed by Northwestern University scientists and show promise in animal trials without obvious side effects.
The Antarctic Ocean has seen a steady increase in sea ice cover over the past three decades, growing by approximately 6,600 square miles annually. This growth is attributed to changes in atmospheric circulation and a depleted ozone layer over Antarctica, which leads to cooling of the stratosphere and strengthening of circumpolar winds.
Salk scientists pinpointed damage to neural stem cells, specifically deformed nuclear envelopes, leading to neuronal loss and dysfunction in Parkinson's patients. The discovery may lead to new diagnostic and therapeutic approaches, including targeted gene-editing technologies.
Researchers at the University of Pennsylvania found a significant association between myasthenia gravis and impaired sense of smell, comparable to Alzheimer's disease and Parkinson's. The study suggests that myasthenia gravis may involve the brain, contrary to its traditional peripheral nervous system classification.
Extradural brain stimulation has been shown to be safe and effective in improving movement disorder symptoms for patients with Parkinson's disease. The technique, called EMCS, provides a less-invasive alternative to electrical deep brain stimulation (DBS) and led to small but significant improvements in voluntary movement control.
Researchers found that rapamycin can extract a balance between UCHL1 and its mirror protein, holding them together in the cytoplasm to correct mistakes in Parkinson's disease. The drug may delay onset of diseases like Alzheimer's and Parkinson's by correcting protein imbalance.
Common sporadic Parkinson's disease arises from excess alpha-synuclein protein in dopamine neurons, which can be treated with drugs targeting elongated transcript forms. A blood test for alpha-synuclein may serve as a biomarker for the disease.
Researchers found that auditory cues had the greatest influence on human gait, while visual cues had no significant effect. The study suggests that auditory cues could be particularly helpful for patients with Parkinson's Disease in their rehabilitation.
New research reveals professional football players are three times more likely to die from brain-damaging diseases compared to the general population. The study found a significant increase in deaths from Alzheimer's disease and ALS among speed position players, highlighting potential risks of chronic traumatic encephalopathy (CTE).
Scientists at UH Center for Nuclear Receptors and Cell Signaling discovered LXRbeta, a nuclear receptor that promotes the survival of dopaminergic neurons, which are the main source of dopamine in the central nervous system. The presence of LXRbeta may offer protection against neurodegeneration of the midbrain.
People with Parkinson's disease performed better on a working memory test after a night's sleep, with slow wave sleep linked to improved performance. Sleep disorders can interfere with this benefit, and dopamine-enhancing medications may play a role in memory improvement.
A study found that caffeine supplements improved Parkinson's severity ratings and speed of movement by 3 points, but did not affect daytime sleepiness or quality of life. The results suggest that caffeine may be a useful treatment option for some patients with Parkinson's disease.
A study at McGill University Health Centre found that caffeine improved motor symptoms in people with Parkinson's disease by increasing speed of movement and reducing stiffness. Larger-scale studies are needed to confirm these findings and explore caffeine as a treatment option.
Researchers have discovered a powerful class of antioxidants that can block the development of Parkinson's disease by bolstering the natural antioxidant Nrf2. The synthetic triterpenoids increased Nrf2 activity, reducing oxidative stress and inflammation in brain cells, which are characteristic of Parkinson's.
Researchers found that severe influenza infection doubles the odds of developing Parkinson's disease later in life, whereas a typical case of red measles as a child reduces the risk by 35%. The study also suggests an association between high-intensity vibrations and increased Parkinson's risk.
Researchers derived iPS cells from patients with genetic forms of Parkinson's and found common signs of distress in neurons, including abnormalities in mitochondria. The cells' responses to treatments depended on the type of Parkinson's each patient had.
Embryonic stem cells can be used to replace dopamine-producing cells in Parkinson's disease patients with high efficiency. Researchers have identified specific genes associated with each stage of neuronal differentiation, allowing for more precise cell purification strategies.
Researchers at BUSM found increased expression of FOXO1 gene in Parkinson's disease brain tissue samples. Two single-nucleotide polymorphisms associated with age at onset were also discovered, providing new insights into the genetic mechanisms of Parkinson's.
A Canadian Mennonite family of Dutch-German-Russian ancestry has contributed to the identification of the DNAJC13 gene associated with late-onset Lewy body Parkinson's disease, according to UBC researchers. The study provides new insights into the genetic aspects of PD and offers hope for effective treatments and a cure.
Researchers have identified a process by which misfolded proteins, such as alpha-synuclein, travel from sick to healthy cells in the brain, leading to the progression of Parkinson's disease. The study provides new insights into the disease's pathology and offers potential targets for disease-modifying treatments.
A study found that deep brain stimulation (DBS) treatment effectively improved motor function in Parkinson's disease patients for at least three years. However, improvements in health-related quality of life and cognitive abilities were gradually lost over time., The treatment was most effective for reducing tremors and muscle rigidity.
Researchers found that urate protects cultured brain cells against Parkinson-like damage by involving astrocytes. The study suggests multiple ways to raise urate levels to protect against neurodegeneration in diseases like Parkinson's.
Researchers found two specific gene variants associated with faster motor decline in Parkinson's patients. These variants can now help doctors predict disease progression, allowing for targeted therapies and faster results on efficacy of drugs.
Researchers at Rush University Medical Center have discovered alpha-synuclein protein in the intestinal wall of patients with early Parkinson's disease, but not healthy subjects. This finding may lead to pre-motor diagnosis and accurate biomarkers for tracking its progress.